Back to top
more

Monopar Therapeutics (MNPR)

(Delayed Data from NSDQ)

$0.66 USD

0.66
39,446

+0.01 (1.08%)

Updated Apr 24, 2024 03:58 PM ET

After-Market: $0.64 -0.02 (-2.59%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy

Monopar Therapeutics (MNPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Monopar Therapeutics (MNPR) Catches Eye: Stock Jumps 11.2%

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.